Skin Cancer Research Review, Issue 5

In this issue:

Real-world efficacy of systemic cytotoxic chemotherapy and EGFR inhibitors in advanced cSCC
CARSKIN reveals a promising efficacy for pembrolizumab monotherapy in PD-L1+ cSCC
KEYNOTE-629 establishes pembrolizumab as a future treatment option for recurrent and/or metastatic cSCC
Real-world efficacy of PD-1 inhibition
Risk of recurrent and metastatic cSCC
Perineural invasion is prognostic of disease recurrence and an unfavourable outcome
An indirect comparison of systemic therapies for advanced cSCC finds a survival benefit to cemiplimab
Perineural invasion, poor differentiation and Breslow>2mm are prognostic for poor outcome in cSCC
Checkpoint inhibitors in solid organ transplant recipients with metastatic cSCC

Please login below to download this issue (PDF)